FINWIRES · TerminalLIVE
FINWIRES

$MEDP

17 stories mentioning MEDPUpdated just now

Every FINWIRES story that references MEDP, newest first.

What are analysts saying about MEDP?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on MEDP?

Insider Trading

Medpace Holdings Insider Sold Shares Worth $6,749,952, According to a Recent SEC Filing

August J. Troendle, 10% Owner, Director, President & CEO, on September 17, 2026, sold 10,880 shares in Medpace Holdings (MEDP) for $6,749,952. Following the Form 4 filing with the SEC, Troendle has control over a total of 5,237,292 common shares of the company, with 504,273 shares held directly and 4,733,019 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1668397/000162205826000014/xslF345X05/wk-form4_1790022182.xml

$MEDP
Insider Trading

Medpace Holdings Insider Sold Shares Worth $403,176, According to a Recent SEC Filing

August J. Troendle, 10% Owner, Director, President & CEO, on August 27, 2026, sold 650 shares in Medpace Holdings (MEDP) for $403,176. Following the Form 4 filing with the SEC, Troendle has control over a total of 5,272,913 common shares of the company, with 539,894 shares held directly and 4,733,019 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1668397/000162205826000010/xslF345X05/wk-form4_1788207113.xml

$MEDP
Insider Trading

Medpace Holdings Insider Sold Shares Worth $2,383,511, According to a Recent SEC Filing

Robert O. Kraft, Director, on August 26, 2026, sold 3,858 shares in Medpace Holdings (MEDP) for $2,383,511. Following the Form 4 filing with the SEC, Kraft has control over a total of 955 common shares of the company, with 955 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1668397/000155859226000010/xslF345X05/wk-form4_1787949166.xml

$MEDP
Insider Trading

Medpace Holdings Insider Sold Shares Worth $2,125,816, According to a Recent SEC Filing

Kevin M. Brady, CFO & Treasurer, on August 20, 2026, sold 3,400 shares in Medpace Holdings (MEDP) for $2,125,816. Following the Form 4 filing with the SEC, Brady has control over a total of 12,830 common shares of the company, with 12,830 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1668397/000089225126000149/xslF345X05/form4.xml

$MEDP
Insider Trading

Medpace Holdings Insider Sold Shares Worth $4,414,590, According to a Recent SEC Filing

Fred B Davenport Jr, Director, on August 19, 2026, sold 7,283 shares in Medpace Holdings (MEDP) for $4,414,590. Following the Form 4 filing with the SEC, Davenport has control over a total of 5,798 common shares of the company, with 3,798 shares held directly and 2,000 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1668397/000089225126000123/xslF345X05/form4.xml

$MEDP
Insider Trading

Medpace Holdings Insider Sold Shares Worth $3,043,150, According to a Recent SEC Filing

Brian T Carley, Director, on August 19, 2026, sold 5,000 shares in Medpace Holdings (MEDP) for $3,043,150. Following the Form 4 filing with the SEC, Carley has control over a total of 27,825 common shares of the company, with 27,825 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1668397/000089225126000124/xslF345X05/form4.xml

$MEDP
Insider Trading

Medpace Holdings Insider Sold Shares Worth $26,281,390, According to a Recent SEC Filing

August J. Troendle, 10% Owner, Director, President & CEO, on August 19, 2026, sold 42,783 shares in Medpace Holdings (MEDP) for $26,281,390. Following the Form 4 filing with the SEC, Troendle has control over a total of 5,294,214 common shares of the company, with 561,195 shares held directly and 4,733,019 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1668397/000089225126000125/xslF345X05/form4.xml

$MEDP
Insider Trading

Medpace Holdings Insider Sold Shares Worth $690,122, According to a Recent SEC Filing

Cornelius P. McCarthy III, Director, on August 11, 2026, sold 1,140 shares in Medpace Holdings (MEDP) for $690,122. Following the Form 4 filing with the SEC, McCarthy has control over a total of 12,275 common shares of the company, with 12,275 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1668397/000175035526000012/xslF345X05/wk-form4_1786651935.xml

$MEDP
Insider Trading

Medpace Holdings Insider Sold Shares Worth $4,500,000, According to a Recent SEC Filing

Susan E Burwig, Executive Vice President, Operations, on July 28, 2026, sold 7,500 shares in Medpace Holdings (MEDP) for $4,500,000. Following the Form 4 filing with the SEC, Burwig has control over a total of 62,984 common shares of the company, with 62,984 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1668397/000167741826000008/xslF345X05/wk-form4_1785357140.xml

$MEDP
Wire

Medpace's Bookings Recovery, Normalization of Cancellations Support Growth, RBC Says

Medpace's (MEDP) recovery in bookings, normalization of cancellations, and pre-backlog pipeline support its growth into 2027, RBC Capital Markets said in a note Thursday.The company's Request for Proposal, or RFP, grew "meaningfully" in Q2 from a year earlier, and pre-backlog awards continued growing faster than backlog itself, the investment firm said.Management expects net bookings to ramp "quite a bit" in H2, provided there isn't a rise in cancellations, according to the note.The firm said Medpace's interim burn rate is expected to remain elevated before a potential gradual decline over the next couple of years as new bookings scale.RBC Capital Markets retained an outperform rating on the stock and increased its price target to $692 from $484.Price: $605.76, Change: $-0.06, Percent Change: -0.01%

$MEDP
Research

RBC Raises Price Target on Medpace Holdings to $692 From $484, Keeps Outperform Rating

Medpace Holdings (MEDP) has an average rating of hold and mean price target of $588.91, according to analysts polled by FactSet.

$MEDP
Wire

Update: Medpace Shares Rise After Q2 Beat

(Updates with the company's latest stock move in the headline and the first paragraph.)Medpace (MEDP) shares surged more than 15.5% in Thursday trading after the company reported stronger-than-expected Q2 earnings and revenue late Wednesday.The company posted Q2 earnings of $4.25 per diluted share, up from $3.10 a year earlier.Analysts polled by FactSet expected $3.98.Revenue for the quarter ended June 30 was $707.3 million, up from $603.3 million a year ago.Analysts expected $689.5 million.For full-year 2026, the company expects EPS of $17.25 to $17.95 per share on revenue of $2.81 billion to $2.89 billion.Analysts expect $16.97 on revenue of $2.77 billion.Price: $610.09, Change: $+81.97, Percent Change: +15.52%

$MEDP
Wire

Medpace Shares Fall After Baird Downgrade

Medpace (MEDP) shares fell 3.2% on Wednesday after Baird downgraded the stock to neutral from outperform and adjusted its price target to $547 per share from $477.Trading volume stood at around 230,600 shares compared with a daily average of 375,188.Price: $528.74, Change: $-17.55, Percent Change: -3.21%

$MEDP
Research

Baird Downgrades Medpace to Neutral From Outperform, Adjusts PT to $547 From $477

Medpace Holdings (MEDP) has an average rating of Hold and mean price target of $462.55, according to analysts polled by FactSet.

$MEDP
Wire

Truist Adjusts Price Target on Medpace to $462 From $539, Maintains Hold Rating

Medpace (MEDP) has an average rating of hold and mean price target of $457.45, according to analysts polled by FactSet.Price: $391.52, Change: $-1.90, Percent Change: -0.48%

$MEDP
Wire

Deutsche Bank Cuts Price Target on Medpace Holdings to $425 From $480, Keeps Hold Rating

Medpace Holdings (MEDP) has an average rating of hold and mean price target of $510.64, according to analysts polled by FactSet.Price: $382.61, Change: $-125.85, Percent Change: -24.75%

$MEDP
Wire

Medpace Q1 Earnings, Revenue Rise

Medpace (MEDP) reported Q1 earnings late Wednesday of $4.28 per diluted share, up from $3.67 a year earlier.Analysts surveyed by FactSet expected $3.92.Revenue for the three months ended March 31 was $706.6 million, up from $558.6 million a year earlier.Analysts polled by FactSet expected $697.6 million.For 2026, the company expects EPS of $16.68 to $17.50 on revenue of $2.76 billion to $2.86 billion. Analysts expect EPS of $17.16 on revenue of $2.81 billion.The company said Jesse Geiger notified his intention to resign as president and that he will retire effective May 31. CEO August Troendle will reassume the role of president until a successor is appointed, the company added.

$MEDP

Track with the FINWIRES app suite

FolioX
FolioX
Track MEDP in your portfolio
WheelAI
WheelAI
Analyze MEDP options with the wheel strategy
StockInsider
StockInsider
See market sentiment on MEDP